🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

Recruitingn/aAges 18 Years - anyAllUniversity Medical Center Groningen
NCT07585890 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given that donor and graft characteristics often predetermine the optimal preservation strategy. Consequently, many studies continue to reference historical benchmark cohorts from the pre-perfusion era, or use risk scores developed before routine utilization of MP. These cohorts, while once valuable, fail to account for the paradigm shift that MP has introduced. Likewise, commonly used donor- and recipient-based risk scores were developed prior to the adoption of MP. While these scores aim to assess survival or morbidity after transplantation, none of them guide decisions about MP use or the most suitable perfusion protocol. As MP technologies continue to evolve there is

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer for patients \>18 years at the time of liver transplantation. * All donor types (DBD, DCD) * Preservation either with static cold storage alone or combined with machine perfusion (MP). * Donor livers underwent MP as part of routine clinical practice and the choice of perfusion protocol was made according to institutional standard practice. * Eligible MP protocols are: 1. end-ischemic single- or dual hypothermic oxygenated MP \[e(D)HOPE\], 2. end-ischemic (back-to-base) normothermic MP \[eNMP\], 3. continuous (device-to-donor) normothermic MP \[cNMP\], 4. e(D)HOPE followed by controlled oxygenated rewarming and normothermic MP \[e(D)HOPE-COR-NMP)\], 5. e(D)HOPE followed by normothermic MP \[e(D)HOPE-NMP\], or 6. Normothermic regional perfusion followed by SCS or an ex situ MP protocol. * A minimum follow-up of 12 months after liver transplantation is required. Exclusion Criteria: * Livers that were allocated to a MP protocol as part of a prospective randomized or interventional clinical trial comparing different preservation techniques or any other invention. * Living donor liver transplantation
💊

What it tests

  • Endischemic hypothermic oxygenated machine perfusion (any device)
  • Endischemic (back-to-base) normothermic machine perfusion (any device)
  • Continuous (device-to-donor) normothermic machine perfusion (any device)
  • Endischemic HOPE-COR-NMP (any device)
  • Endischemic HOPE-NMP (any device)
📍

Where

37 sites
Medical University of Innsbruck
Innsbruck, Austria
Medical University of Vienna
Vienna, Austria
Cliniques universitaires Saint-Luc
Brussels, Belgium
UZ Ghent
Ghent, Belgium
University Hospitals Leuven
Leuven, Belgium
CHU de Liège
Liège, Belgium
Beaujon Hospital
Clichy, France
Hautepierre Hospital
Strasbourg, France

…and 29 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy